|Items||Size （2mg）||Size（5mg X 2）|
|Particle size||2 μm||2 μm|
|Physical appearance||Powder mixture||Powder mixture|
|Amount of Coupled Protein||>938 pmol (9 μg) BCMA/mg Beads||>938 pmol (9 μg) BCMA/mg Beads|
|Binding Capacity||>267 pmol (40 μg) antibody/mg beads||>267 pmol (40 μg) antibody/mg beads|
|Formulation||PBS, pH7.4, with 10% Trehalose||PBS, pH7.4, with 10% Trehalose|
|Reconstitution||2 mL ultrapure water (1 mg beads/mL)||5 mL ultrapure water (1 mg beads/mL)|
Upon receipt, please store the lyophilized beads at -20℃ for long term storage. The shelf life is 1 year at -20℃ in lyophilized form.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.
Add BCMA pre-coupling magnetic beads into each well at a concentration of 1 mg/ml. 0.1 mg beads was added to each well. Then add increasing concentrations of anti-BCMA antibody to different wells. PE-labeled anti-human IgG Fc antibody was used for detection (QC tested).
The binding curves between BCMA pre-coupling magnetic beads (Cat. No. MBS-K004) after different freeze-thaw cycles and anti-BCMA antibody. 0.1 mg of Beads (1 mg/mL, 100 μL) was washed three times and the supernatant was removed. 100 μL antibodies of the corresponding concentration (10 μg/mL-0.039 μg/mL) were added. Fluorescent labeled secondary antibody was added for detection (Routinely tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.